First ever MASH drug primed for big impact in USA
Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). Madrigal Pharmaceuticals (Nasdaq: MDGL) recently scored a US Food and Drug Administration (FDA) nod for Rezdiffra (resmetirom) as a treatment for MASH, alongside diet and exercise. As the first prescription medicine for a large treatment opportunity, Rezdiffra has the […]
Docs sing praises of Madrigal’s Rezdiffra, predict rapid uptake
Madrigal Pharmaceuticals already has physicians singing from its hymn sheet. Shortly after the biotech won approval in metabolic dysfunction-associated steatohepatitis (MASH), most gastroenterologists said they were familiar with its drug and planning to trial the brand within six months of its launch. Spherix Global Insights captured the views in a survey that asked 81 gastroenterologists for their […]
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
In its first few months of U.S. availability, Pfizer’s Velsipity has already made a splash in the moderate to severe ulcerative colitis (UC) space, where it’s up against BMS’ Zeposia, a fellow S1P receptor modulator, as well as biologics including AbbVie’s Humira and Rinvoq, J&J’s Stelara, Takeda’s Entyvio and Eli Lilly’s Omvoh, the last two […]
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks to the surprising resilience of AbbVie’s autoimmune blockbuster. Now, in the face of lackluster Cytelzo sales, Boehringer has decided to prune its ranks in the U.S. and adopt […]
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Excitement grows as the FDA’s first approval for MASH treatment nears commercialization, according to Spherix Global Insights. Exton, PA., April 5, 2024 – As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) is poised to make a sizable impact on a condition with substantial unmet need. As […]
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
Research conducted by Spherix Global Insights reveals Retinal Specialists likely to adopt gene therapies. Exton, PA., March 19, 2024 – Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and […]
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
Spherix Global Insights’ fourth annual IgAN patient chart audit reveals continued shifts in the IgAN treatment paradigm with the use of SGLT2 inhibitors, TARPEYO (Calliditas), and FILSPARI (Travere Therapeutics). EXTON, Pa., March 12, 2024 – The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of […]
How Do Companies Avert Further Frustration Among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements. EXTON, PA., March 12, 2024 — For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming months may prove equally heart-wrenching. They face the daunting responsibility of informing patients and caregivers that not […]
Charting New Paths: Non-TNF’s Evolving in Rheumatoid Arthritis Market
Although crowded, the RA market contains clear pathways for existing players and new entrants to navigate the evolving landscape and expand their market share, according to Spherix Global Insights. EXTON, PA., February 23, 2024 — Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer […]
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
Adoption of Leqembi is even slower than expected. EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical community and among families nationwide. The debut of Aduhelm from Biogen in 2021 brought with it a wave of […]
